Profile data is unavailable for this security.
About the company
PureTech Health plc (PureTech) is a biotherapeutics company engaged in the treatment paradigm for devastating diseases. The Company has created a pipeline through its experienced research and development team and its network of scientists, clinicians, and industry leaders. The pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 27 therapeutics and therapeutic candidates, including two that have received both United States (U.S.) Food and Drug Administration (FDA) clearance and European marketing authorization. All of the underlying programs and platforms that resulted in the pipeline of therapeutic candidates are identified or discovered and then advanced by the PureTech team through key validation points based on insights in immunology and drug development. The Company's wholly owned pipeline consists of various programs, including LYT-100, LYT-200, LYT-210, LYT-300, LYT-500, LYT-510, and LYT-503/IMB-150.
- Revenue in GBP (TTM)15.25m
- Net income in GBP-11.08m
- Incorporated2015
- Employees95.00
- LocationPureTech Health PLC6 Tide Street, Suite 400BOSTON 02210United StatesUSA
- Phone+1 (617) 482-2333
- Fax+1 (617) 482-3337
- Websitehttp://puretechhealth.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scancell Holdings Plc | 0.00 | -2.07m | 190.76m | 40.00 | -- | 10.53 | -- | -- | -0.0027 | -0.0027 | 0.00 | 0.0222 | 0.00 | -- | -- | 0.00 | -4.72 | -31.06 | -4.99 | -33.18 | -- | -- | -- | -- | -- | -- | 0.3111 | -- | -- | -- | 86.66 | -- | 83.42 | -- |
| Bioventix PLC | 11.72m | 7.67m | 191.18m | 17.00 | 25.15 | 16.17 | 24.46 | 16.31 | 1.46 | 1.46 | 2.23 | 2.27 | 0.9006 | 1.79 | 2.38 | -- | 58.98 | 53.92 | 64.59 | 57.75 | 93.94 | 92.55 | 65.48 | 64.96 | 9.07 | -- | -- | 76.92 | 7.22 | 10.09 | 14.01 | 9.29 | -11.53 | 19.83 |
| Faron Pharmaceuticals Oy | 0.00 | -20.46m | 193.57m | 37.00 | -- | -- | -- | -- | -0.389 | -0.389 | 0.00 | -0.0809 | 0.00 | -- | -- | 0.00 | -166.26 | -165.50 | -342.16 | -391.61 | -- | -- | -- | -487,178.90 | -- | -- | 1.73 | -- | -- | -- | -25.16 | -- | 38.80 | -- |
| Redx Pharma PLC | 16.29m | -18.62m | 204.30m | 71.00 | -- | 31.21 | -- | 12.54 | -0.0679 | -0.0679 | 0.0594 | 0.0195 | 0.38 | -- | 46.40 | 229,394.40 | -43.45 | -40.30 | -63.41 | -66.57 | -- | -- | -114.35 | -85.78 | -- | -10.98 | 0.7683 | -- | 76.52 | -- | -134.19 | -- | 11.17 | -- |
| Alliance Pharma plc | 163.34m | 12.18m | 247.32m | 250.00 | 20.56 | 0.8325 | 10.78 | 1.51 | 0.0223 | 0.0223 | 0.3018 | 0.5501 | 0.3075 | 2.37 | 4.68 | 640,560.80 | 2.29 | 4.23 | 2.50 | 4.82 | 66.42 | 63.24 | 7.46 | 13.50 | 1.47 | 13.44 | 0.3145 | 39.33 | 25.74 | 10.85 | -8.82 | -16.56 | 31.70 | 6.92 |
| Avacta Group Plc | 6.14m | -25.17m | 284.45m | 133.00 | -- | 7.55 | -- | 46.35 | -0.1005 | -0.0961 | 0.0245 | 0.1417 | 0.116 | 12.05 | 0.9818 | 46,142.86 | -47.59 | -- | -52.99 | -- | 59.26 | -- | -410.09 | -- | 4.96 | -38.04 | 0.1183 | -- | 37.17 | -- | -60.85 | -- | -- | -- |
| Oxford BioMedica plc | 125.57m | -24.54m | 401.42m | 959.00 | -- | 1.62 | -- | 3.20 | -0.262 | -0.262 | 1.39 | 2.58 | 0.378 | 4.45 | 2.52 | 154,076.10 | -8.04 | -0.756 | -11.40 | -0.9976 | 60.43 | 55.20 | -21.26 | -1.20 | 1.71 | -11.23 | 0.2925 | -- | 62.77 | 38.74 | 404.42 | -- | 7.94 | -- |
| Ergomed PLC | 132.46m | 13.36m | 671.27m | 1.26k | 50.79 | 8.89 | 35.87 | 5.07 | 0.2634 | 0.2634 | 2.62 | 1.50 | 1.22 | -- | 4.60 | 105,542.60 | 12.33 | 4.27 | 18.56 | 6.13 | 40.97 | 41.18 | 10.08 | 3.85 | -- | 53.13 | 0.0333 | 0.00 | 37.26 | 24.76 | 30.90 | -- | -2.38 | -- |
| Puretech Health PLC | 15.25m | -11.08m | 827.04m | 95.00 | -- | 1.79 | -- | 54.25 | -0.0384 | -0.0384 | 0.053 | 1.66 | 0.0216 | -- | 4.76 | 160,485.90 | -1.00 | 4.86 | -1.26 | 6.24 | -- | -- | -46.43 | 260.53 | -- | -- | 0.0771 | 0.00 | 47.76 | 31.45 | -1,111.83 | -- | 9.02 | -- |
| Genus plc | 593.40m | 40.90m | 2.01bn | 3.33k | 48.95 | 3.47 | 26.52 | 3.38 | 0.6235 | 0.6235 | 9.04 | 8.80 | 0.635 | -- | 5.04 | 178,466.20 | 3.93 | 3.23 | 4.64 | 3.80 | -- | -- | 6.18 | 5.04 | 1.37 | 113.60 | 0.2812 | 67.18 | 3.33 | 5.27 | -13.53 | 4.51 | 28.18 | 6.28 |
| Worldwide Healthcare Trust PLC | -59.72m | -84.06m | 2.14bn | 0.00 | -- | 0.9378 | -- | -- | -1.28 | -1.28 | -0.9149 | 35.51 | -0.0233 | -- | -- | -- | -3.28 | 7.07 | -3.57 | 7.52 | -- | 86.92 | -- | 84.78 | -- | -- | 0.00 | 10.32 | -125.52 | -- | -129.67 | -- | -- | 3.33 |
| Indivior PLC | 724.48m | 136.20m | 2.37bn | 802.00 | 18.84 | 12.81 | 14.96 | 3.27 | 0.9195 | 0.9195 | 4.89 | 1.35 | 0.5239 | 1.52 | 4.77 | 903,346.40 | 9.85 | 6.98 | 17.34 | 14.26 | 82.56 | 86.32 | 18.80 | 12.43 | 1.56 | 10.56 | 0.5487 | 0.00 | 22.26 | -5.65 | 238.51 | 42.41 | -0.5781 | -- |
Data as of Dec 06 2022. Currency figures normalised to PureTech Health PLC's reporting currency: UK Pound GBX
61.80%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Invesco Asset Management Ltd.as of 07 Oct 2022 | 64.58m | 23.16% |
| Lansdowne Partners (UK) LLPas of 10 Oct 2022 | 25.36m | 9.09% |
| Baillie Gifford & Co.as of 07 Oct 2022 | 21.02m | 7.54% |
| Jupiter Asset Management Ltd.as of 15 Jul 2020 | 14.25m | 5.11% |
| M&G Investment Management Ltd.as of 07 Oct 2022 | 12.54m | 4.50% |
| Miller Value Partners LLCas of 31 Mar 2021 | 10.04m | 3.60% |
| Eurizon Capital SGR SpAas of 01 Nov 2022 | 9.56m | 3.43% |
| Hargreave Hale Ltd.as of 07 Oct 2022 | 5.34m | 1.92% |
| Canaccord Genuity Wealth Ltd.as of 01 Nov 2022 | 5.15m | 1.85% |
| DNCA Finance SAas of 30 Jun 2022 | 4.50m | 1.61% |
More ▼
Data from 30 Sep 2022 - 30 Nov 2022Source: FactSet Research Systems Inc.
